Podcast

Pharmacy Focus: Psychedelic Pharmacy - Episode 5

Kelsey Ramsden, co-founder, president, and CEO at MindCure, discussed the potential links between sexual trauma and hypoactive sexual desire disorder in women.

In part 2 of the discussion with Kelsey Ramsden, co-founder, president, and CEO at MindCure, Ramsden discussed the potential links between sexual trauma and hypoactive sexual desire disorder in women. She also discussed how MDMA-assisted psychotherapy could help treat the disorder.

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Trisha Winroth, PharmD, and Ashly McPhillips, PharmD
Naloxone concept represented by wooden letter tiles.
Related Content
Hidradenitis Suppurative, FDA, Dermatology, Bimzelx | Image Credit: © Gorodenkoff | stock.adobe.com
Published: November 20th 2024 | Updated: November 20th 2024

FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa

Ashley Gallagher, Associate Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Mid section of pregnant woman standing in corridor
November 15th 2024

Intravenous Immunoglobulin Elicits Favorable Response in Pregnant Patient With Pemphigoid Gestationis

Luke Halpern, Assistant Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Biosimilar, Ocrelizumab, Multiple Sclerosis | Image Credit: ralwel - stock.adobe.com
November 12th 2024

Proposed Biosimilar to Ocrelizumab Shows Comparability With Reference Product

Ashley Gallagher, Associate Editor
Diabetes, Cagrilintinide, Semagliutide | Image Credit: millaf - stock.adobe.com
November 11th 2024

An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 Trials

Vidhi Patel, PharmD Candidate